Skip to main content

Advertisement

SpringerLink
Log in

Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation

  • Case Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Pulmonary enteric adenocarcinoma (PEAC) is a rare lung adenocarcinoma with morphological and immunohistochemical similarities to colorectal adenocarcinoma and intestinal differentiation. PEAC belongs to the group of non-small-cell lung carcinoma (NSCLC) and is defined as having a more than 50% intestinal differentiation component. We report a postoperative (T4N2M0 stage IIIb) PEAC patient with EGFR L858R + A871G combined mutation. Following surgery, the patient underwent treatment with the first-generation EGFR-TKI, gefitinib, and achieved an impressive 5-year progression-free survival (PFS). This suggests that gefitinib may serve as an effective treatment option for PEAC patients with EGFR L858R + A871G compound mutations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A, Cancer statistics (2020) CA Cancer J Clin. 2020 Jan;70(1):7–30

  2. Li H, Cao W (2020 Jun) Pulmonary enteric adenocarcinoma: a literature review. J Thorac Dis 12(6):3217–3226

  3. Gong J, Fan Y, Lu H (2021 Aug) Pulmonary enteric adenocarcinoma. Transl Oncol 14(8):101123

  4. Guo Y, Song J, Wang Y, Huang L, Sun L, Zhao J, Zhang S, Jing W, Ma J, Han C (2020) Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR-TKIs in EGFR-Mutant Non-small Cell Lung Cancer: a review. Front Oncol 10:610923

    Article  PubMed  PubMed Central  Google Scholar 

  5. Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, Poteete A, Rinsurongkawong W, Zhang X, Ren C, Liu X, Hong L, Zhang J, Diao L, Madison R, Schrock AB, Saam J, Raymond V, Fang B, Wang J, Ha MJ, Cross JB, Gray JE, Heymach JV (2021) Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 597(7878):732–737

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS, Costa DB (2013) Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8:45–51

    Article  PubMed  PubMed Central  Google Scholar 

  7. Jin LL, Wu ZZ, Wang YL, Chen DS, Li S, Xiao M, Zhao X (2021) Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation. Invest New Drugs 39(5):1419–1421

    Article  CAS  PubMed  Google Scholar 

  8. Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang H, Song Y, Wu YL, Xu N, Zhou J, Luo R, Bai C, Jin Y, Liu W, Wei Z, Tan F, Wang Y, Ding L, Dai H, Jiao S, Wang J, Liang L, Zhang W, Sun Y (2013) Icotinib versus Gefitinib in previously treated advanced non-small-cell Lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 14(10):953–961

    Article  CAS  PubMed  Google Scholar 

  9. Liu Y, Wang H, Yang S, Yang Y, Wu Y, He Z, Ma S, Mo Y, Chen H, Wang Q, Ge H (2022 Jun) EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors. J Thorac Dis 14(6):2254–2267

  10. Kamath A, Joseph AM, Gupta K, Behera D, Jaiswal A, Dewan R, Rajala MS (2015) Proteomic analysis of HEK293 cells expressing non small cell lung carcinoma associated epidermal growth factor receptor variants reveals induction of heat shock response. Exp Hematol Oncol 4:16

    Article  PubMed  PubMed Central  Google Scholar 

  11. Fu J, Tong Y, Xu Z, Li Y, Zhao Y, Wang T, Li C, Cang S (2023) Impact of TP53 mutations on EGFR-Tyrosine kinase inhibitor efficacy and potential treatment strategy. Clin Lung Cancer 24(1):29–39

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to express their gratitude to Edit Springs (https://www.editsprings.cn ) for the expert linguistic services provided.

Funding

Hebei Youth Science and Technology Program (Department of Health) Project No.: 20220882.

Author information

Authors and Affiliations

  1. Hebei General Hospital Shijiazhuang, Shijiazhuang, Hebei, 050000, China

    Yujie Cui, Miaomiao Liu, Qi Zhang & Hongzhen Zhang

  2. Graduate School of Hebei North College Zhangjiakou, Zhangjiakou, Hebei, 075000, China

    Jinlong Liang & Xiyun Kang

Authors
  1. Yujie Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jinlong Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiyun Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miaomiao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hongzhen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

C and L drafted the paper. These authors contributed equally to this work and share first authorship. Z revised the paper. This paper are translated by K. L and Z did literature search. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Hongzhen Zhang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cui, Y., Liang, J., Kang, X. et al. Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation. Invest New Drugs 41, 787–790 (2023). https://doi.org/10.1007/s10637-023-01401-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-023-01401-3

Keywords

Search

Navigation